Genetically altered malaria vaccine shows promise in early human trial
NCT ID NCT06735209
First seen Sep 30, 2025 · Last updated May 06, 2026 · Updated 26 times
Summary
This early-stage study tests a new malaria vaccine made from weakened parasites that are designed to stop growing late in the liver, before causing blood infection. About 22 healthy adults who have never had malaria will receive the vaccine or a placebo to check for safety and immune response. The goal is to see if this vaccine is safe and can better protect against malaria than earlier versions.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MALARIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
The University of Washington - Virology Research Clinic
Seattle, Washington, 98104, United States
Conditions
Explore the condition pages connected to this study.